Scribe Therapeutics prices IPO at $15 per share on Nasdaq By Investing.com
Scribe Therapeutics Inc. (Nasdaq: SCTX) priced its IPO at $15.00 per share, the top of its range, selling 8.58 million shares for expected gross proceeds of about $128.7 million. The offering was upsized and includes a 30-day option for 1.287 million more shares. Shares start trading July 24, 2026, with a concurrent $15.00 private placement of 500,000 shares to Sanofi.
How this was made
The 30-second read
Why it matters
The IPO terms (high-end $15 price, upsized share count, expected gross proceeds, and concurrent Sanofi private placement) are actionable for positioning around first trading day and for assessing dilution and demand signals.
Market read
This is a primary capital-raise disclosure with specific pricing and timing, which can drive immediate trading decisions for IPO allocation, first-day risk, and biotech IPO sentiment.
What to watch
Concurrent Sanofi private placement and the 30-day underwriter option can affect post-IPO float dynamics and near-term trading liquidity beyond the headline IPO size.
Background
Scribe Therapeutics is a clinical-stage biotech focused on CRISPR-based genetic medicines, with initial programs targeting cardiometabolic disease.
Ticker impact
Scribe Therapeutics priced its IPO at $15 per share, upsized to 8.58M shares, and set a Nasdaq trading start date of July 24, 2026.
Likely elevated first-day volatility; direction depends on demand versus the high-end pricing and broader biotech risk appetite.
The article discloses concrete capital-market terms (price, share count, proceeds, underwriter option) and a concurrent Sanofi private placement, which can affect sentiment and trading flows at listing.
Market effects
Adds a fresh, high-end priced supply event in clinical-stage CRISPR biotech, which can influence near-term sentiment toward similar pre-revenue issuers.
Primarily US-focused via Nasdaq listing and US capital markets activity.
Limited global read-through beyond biotech IPO appetite and cross-border strategic interest (Sanofi private placement).
Counterpoint
High-end pricing can signal strong demand, but it can also mean the stock is already priced for optimism, leaving less upside on day one.
Key entities
- companyScribe Therapeutics Inc.
Clinical-stage CRISPR biotech that priced its Nasdaq IPO at $15 per share and will begin trading July 24, 2026.
- strategic_partnerSanofi
Agreed to buy 500,000 shares in a concurrent private placement at $15 per share, expected to close July 27, 2026.
- venueNasdaq Global Market
Exchange where Scribe Therapeutics shares are set to begin trading on July 24, 2026.
